Skip to reading
Compare
PeptideInstitute

Ipamorelin was watched through a short opening.

Two hours sounds like a simple answer. It helps to know what researchers measured in those hours, and what a later hospital trial found.

Open the Oath Research notice (codes & research card).

Ipamorelin: 20% for a first order, 15% for any order

Oath Research lists Ipamorelin among its research peptides at oathresearch.com. This notice concerns research materials, not a medicine or a treatment.

GRANT takes 20% off a new customer's first order.

GRANT15 gives 15% off for everyone on any order. No minimum. Applies to repeat orders.

Both codes are current. Applying either one makes no payment to this site.

Oath Research Ipamorelin, sold as research material at oathresearch.com

What are the current Oath Research codes for Ipamorelin?

For Ipamorelin, GRANT takes 20% off the first order at oathresearch.com for new customers. GRANT15 takes 15% off any order for every customer.

Two hours in which study?

Ipamorelin acts on the same body switch as ghrelin, a hormone involved in hunger and growth hormone release. That explains why researchers became interested. It doesn't tell us whether people feel or function better.

In a study in healthy men given ipamorelin into a vein, its half-life was about two hours. Half-life is the time for the compound's blood concentration to fall by half. The study also watched the burst of growth hormone that followed.

That route matters. A result from an infusion into a vein doesn't establish what happens with an injection under the skin. It also doesn't give us a treatment schedule.

Could people eat sooner?

A later trial in adults after bowel surgery asked a more everyday question: could they tolerate a meal sooner? The main result didn't show a statistically significant benefit over placebo, a dummy treatment. The apparent difference wasn't convincing enough to establish that benefit.

That result deserves space beside the hormone study. A compound can change a signal inside the body without showing the hoped-for improvement in a trial. The signal and the improvement aren't the same thing.

Neither published study established better sleep, fat loss or training recovery. Those claims need studies that actually measure them. A hormone result can't fill in the blanks.

What we still don't know

Ipamorelin has no FDA-approved medical use. The FDA review raises concerns about immune reactions and missing long-term safety work. The surgery study recorded two deaths among people receiving ipamorelin. Both patients had complications following surgery for colon cancer. FDA's review leaves ipamorelin's role unresolved and treats those deaths as a safety concern.

The FDA page current as of April 22, 2026 keeps ipamorelin acetate in Category 2 for 503B outsourcing facilities, a type of compounder. It also lists withdrawn nominations. Taking a request back isn't clearance or approval.

The useful takeaway is small: a short hormone study and a hospital trial that didn’t establish its main benefit. The reading questions explain how to keep those limits attached to the claims.